BR112013023280A2 - uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune - Google Patents

uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune

Info

Publication number
BR112013023280A2
BR112013023280A2 BR112013023280A BR112013023280A BR112013023280A2 BR 112013023280 A2 BR112013023280 A2 BR 112013023280A2 BR 112013023280 A BR112013023280 A BR 112013023280A BR 112013023280 A BR112013023280 A BR 112013023280A BR 112013023280 A2 BR112013023280 A2 BR 112013023280A2
Authority
BR
Brazil
Prior art keywords
oxoquinazoline
dione
piperidine
inflammatory
amino
Prior art date
Application number
BR112013023280A
Other languages
English (en)
Inventor
Gandhi Anita
H Schafer Peter
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112013023280A2 publication Critical patent/BR112013023280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Electromagnetism (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
BR112013023280A 2011-03-11 2012-03-09 uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune BR112013023280A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451995P 2011-03-11 2011-03-11
US201161480272P 2011-04-28 2011-04-28
PCT/US2012/028538 WO2012125475A1 (en) 2011-03-11 2012-03-09 Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases

Publications (1)

Publication Number Publication Date
BR112013023280A2 true BR112013023280A2 (pt) 2017-09-19

Family

ID=45876915

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013023280A BR112013023280A2 (pt) 2011-03-11 2012-03-09 uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune
BR112013023277A BR112013023277A2 (pt) 2011-03-11 2012-03-09 métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013023277A BR112013023277A2 (pt) 2011-03-11 2012-03-09 métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona

Country Status (29)

Country Link
US (6) US20140148473A1 (pt)
EP (3) EP2683383B1 (pt)
JP (5) JP2014510078A (pt)
KR (2) KR20140019364A (pt)
CN (3) CN107375293A (pt)
AR (1) AR085651A1 (pt)
AU (4) AU2012229300B2 (pt)
BR (2) BR112013023280A2 (pt)
CA (2) CA2829592A1 (pt)
CY (1) CY1117430T1 (pt)
DK (1) DK2683384T3 (pt)
EA (2) EA201391319A1 (pt)
ES (2) ES2659205T3 (pt)
HK (1) HK1191858A1 (pt)
HR (1) HRP20160056T1 (pt)
HU (1) HUE027481T2 (pt)
IL (2) IL227990B (pt)
MX (2) MX2013010153A (pt)
NI (2) NI201300082A (pt)
PL (1) PL2683384T3 (pt)
PT (1) PT2683384E (pt)
RS (1) RS54553B1 (pt)
RU (3) RU2013145556A (pt)
SG (2) SG192947A1 (pt)
SI (1) SI2683384T1 (pt)
SM (1) SMT201600034B (pt)
TW (2) TW201700100A (pt)
WO (2) WO2012125475A1 (pt)
ZA (2) ZA201306148B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP6016892B2 (ja) * 2011-04-29 2016-10-26 セルジーン コーポレイション セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
WO2014004990A2 (en) 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
EP2882442B1 (en) * 2012-08-09 2021-06-09 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9682952B2 (en) 2012-09-04 2017-06-20 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
BR112015005243A2 (pt) * 2012-09-10 2017-07-04 Celgene Corp métodos para o tratamento de câncer de mama localmente avançado
CA2935495C (en) * 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
CA2909625C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CN105392499B (zh) * 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
SI2991976T1 (sl) * 2013-05-01 2017-11-30 Celgene Corporation Sintheza 3-(5-amino-2-metil-4-oksokvinazolin-3(4H)-il)piperidin-2,6- diona
TW201534305A (zh) * 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
EA201691144A1 (ru) * 2013-12-06 2016-11-30 Селджин Корпорейшн Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
CN107073122A (zh) * 2014-07-11 2017-08-18 细胞基因公司 恶性肿瘤的联合治疗
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
MX2017005163A (es) 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
TW201642857A (zh) * 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN107921004A (zh) * 2015-08-27 2018-04-17 细胞基因公司 包含3‑(5‑氨基‑2‑甲基‑4‑氧代基‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的药物组合物
US11459613B2 (en) 2015-09-11 2022-10-04 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of Cereblon
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
EP3383398A1 (en) * 2015-12-02 2018-10-10 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3404024B1 (en) 2016-01-14 2020-11-18 Kangpu Biopharmaceuticals, Ltd. Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
AU2017232906B2 (en) * 2016-03-16 2022-03-31 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector T cell function
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US20180258064A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
ES2959860T3 (es) * 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
WO2019077968A1 (en) 2017-10-18 2019-04-25 Canon Kabushiki Kaisha PACKAGING CONTAINER AND PACKAGE
EP3774815A1 (en) * 2018-03-30 2021-02-17 Biotheryx Inc. Thienopyrimidinone compounds
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
JP7323603B2 (ja) * 2018-09-07 2023-08-08 メッドシャイン ディスカバリー インコーポレイテッド 三環式縮合フラン置換ピペリジンジオン系化合物
WO2020072334A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
US20220178929A1 (en) * 2019-03-22 2022-06-09 University Of Ulsan Foundation For Industry Cooperation Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto
EP4126847A1 (en) * 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2024040036A2 (en) * 2022-08-16 2024-02-22 iTeos Belgium SA Adenosine receptor antagonists and compositions thereof for use in the treatment of disease associated with expression of at least one antibody-secreting cell marker

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
YU45103A (sh) * 2000-12-06 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba sarp/1 za lečenje i prevenciju skleroderme
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
JP2008520207A (ja) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
JP5388854B2 (ja) * 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
GB0709092D0 (en) * 2007-05-11 2007-06-20 Borrebaeck Carl Diagnosis and method of disease
BRPI0817525A2 (pt) * 2007-09-26 2014-11-18 Celgene Corp Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
MX2010006092A (es) * 2007-12-07 2010-07-05 Celgene Corp Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona.
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
JP6016892B2 (ja) * 2011-04-29 2016-10-26 セルジーン コーポレイション セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法

Also Published As

Publication number Publication date
EA201391319A1 (ru) 2014-03-31
EP2683384A1 (en) 2014-01-15
US20140148473A1 (en) 2014-05-29
CA2829593A1 (en) 2012-09-20
ZA201306305B (en) 2014-10-29
TW201700100A (zh) 2017-01-01
AU2012229300B2 (en) 2017-04-20
IL227990A0 (en) 2013-09-30
AR085651A1 (es) 2013-10-16
ES2562332T3 (es) 2016-03-03
EA201691939A1 (ru) 2017-05-31
JP2017081959A (ja) 2017-05-18
WO2012125459A1 (en) 2012-09-20
TW201242601A (en) 2012-11-01
JP6118273B2 (ja) 2017-04-19
RU2013145524A (ru) 2015-04-20
JP2014508780A (ja) 2014-04-10
PL2683384T3 (pl) 2016-06-30
SG192947A1 (en) 2013-09-30
NI201300081A (es) 2014-02-25
JP2017101052A (ja) 2017-06-08
SG193320A1 (en) 2013-10-30
EP2683383A1 (en) 2014-01-15
IL227990B (en) 2018-02-28
SMT201600034B (it) 2016-04-29
WO2012125475A1 (en) 2012-09-20
SI2683384T1 (sl) 2016-05-31
US20170165266A1 (en) 2017-06-15
KR20140025374A (ko) 2014-03-04
AU2012229316A1 (en) 2013-09-19
CN103561744A (zh) 2014-02-05
CN107375293A (zh) 2017-11-24
JP6348192B2 (ja) 2018-06-27
CN103561743A (zh) 2014-02-05
BR112013023277A2 (pt) 2017-06-27
DK2683384T3 (da) 2016-02-08
EP2683383B1 (en) 2017-11-29
ES2659205T3 (es) 2018-03-14
ZA201306148B (en) 2014-10-29
US20120230983A1 (en) 2012-09-13
HK1191858A1 (zh) 2014-08-08
US20150126538A1 (en) 2015-05-07
RU2017120977A (ru) 2018-11-15
NZ614347A (en) 2015-09-25
HUE027481T2 (en) 2016-09-28
PT2683384E (pt) 2016-03-11
US8906932B2 (en) 2014-12-09
EP2683384B1 (en) 2015-12-09
AU2012229300A1 (en) 2013-09-12
AU2012229316B2 (en) 2017-05-11
CY1117430T1 (el) 2017-04-26
CA2829592A1 (en) 2012-09-20
JP2018168159A (ja) 2018-11-01
JP2014510078A (ja) 2014-04-24
TWI542349B (zh) 2016-07-21
HRP20160056T1 (hr) 2016-02-12
US20160136167A1 (en) 2016-05-19
RU2013145556A (ru) 2015-04-20
US20180055844A1 (en) 2018-03-01
RS54553B1 (en) 2016-06-30
EP3025715A1 (en) 2016-06-01
MX2013010153A (es) 2013-09-26
KR20140019364A (ko) 2014-02-14
IL228230A (en) 2017-03-30
AU2017204402A1 (en) 2017-07-20
AU2017210633A1 (en) 2017-08-24
MX2013010217A (es) 2013-10-25
NZ614493A (en) 2016-01-29
NI201300082A (es) 2014-02-25

Similar Documents

Publication Publication Date Title
BR112013023280A2 (pt) uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune
IL285474A (en) Anti- pdl1 antibody compositions
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
HRP20181172T1 (hr) Derivati pirazolpirimidina supstituirani na poziciji 4, te njihova uporaba u proizvodnji lijekova
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
BR112013012126A2 (pt) sistema de fumar eletricamente aquecido compreendendo pelo menos duas unidades
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
HK1212255A1 (en) Artemisinin and its derivatives for use in the treatment of kidney disease
HK1198031A1 (zh) 有用於治療濫用藥物及酒精的 衍生物
AP2015008860A0 (en) Collection systems for use in offset pit latrines having pour-flush latrine pans, collectors, offsetpit latrines, and related methods
EP2692382A4 (en) RUNNING SYSTEM AND HEATING DEVICE USED IN THIS RUNNING SYSTEM
DK3238578T3 (da) Funktionel måtte til hjælp til dyb søvn hos spædbarn
DK2552250T3 (da) Supramolekylær kompleks aroma immobilisering og kontrolleret frigivelse
PL2996661T3 (pl) Zestaw do jednorazowego użytku do przygotowywania substancji aktywnych przez rozpuszczanie i/lub podgrzewanie
GB201211888D0 (en) Device and method for supporting people in the home environment
FR2979230B1 (fr) Fauteuil automoteur pour personne handicapee
ES1077536Y (es) Cuchara perfeccionada para utilización por bebes y personas con minusvalías motrices.
DK2997307T4 (da) Anordning og fremgangsmåde i kedel med fluidiseret leje-teknologi
TH1401006251A (th) 1h-ไพราโซโล[3,4-b]ไพริดีนและการนำไปใช้ในการรักษาโรค
TH1401003659A (th) ไนฟูราเทลซัลฟอกไซด์สำหรับการใช้ในการรักษาการติดเชื้อแบคทีเรีย

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]